CLAZ.F Stock Overview
A clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Claritas Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.000001 |
| 52 Week High | CA$0.0002 |
| 52 Week Low | CA$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLAZ.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -0.9% |
| 1Y | n/a | 23.5% | 38.9% |
Return vs Industry: Insufficient data to determine how CLAZ.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CLAZ.F performed against the US Market.
Price Volatility
| CLAZ.F volatility | |
|---|---|
| CLAZ.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLAZ.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CLAZ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Bob Farrell | claritaspharma.com |
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Claritas Pharmaceuticals, Inc. Fundamentals Summary
| CLAZ.F fundamental statistics | |
|---|---|
| Market cap | US$679.77k |
| Earnings (TTM) | US$1.81m |
| Revenue (TTM) | n/a |
0.0x
P/E Ratio0.0x
P/S RatioIs CLAZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLAZ.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$1.80m |
| Earnings | US$1.81m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CLAZ.F perform over the long term?
See historical performance and comparison